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Abstract 
 
LESLIE M. BAGGESEN: ARFI-Monitored Hemostatic  
Challenge for Assessment of In Vivo Hemostasis in Canine Models of Inherited  
Bleeding Disorders 
(Under the direction of Caterina M. Gallippi, Ph.D.) 
 
 
The need for a validated in vivo assay to test the efficacy and safety of therapeutic 
agents for hemostatic disorders is paramount as new clotting factor replacement therapies 
are developed. Current hemostatic assays are almost exclusively ex vivo. Conventional in 
vivo assays are limited in application to relevant animal models, and suffer from a lack of 
reproducibility. This thesis demonstrates that Acoustic Radiation Force Impulse - 
Monitored Hemostatic Challenge (ARFI-MHC) may be an alternative in vivo assay for 
the measurement of hemostatic metrics. Time to hemostasis (TTH) and rate of 
hemorrhage (RH) were measured in dogs for six hemostatic phenotypes. Two algorithms 
were compared for TTH and RH measurements with spatial clustering for noise 
reduction. Each method was evaluated for reproducibility and validated using autologous 
blood infusions. ARFI-MHC was capable of distinguishing bleeding phenotypes based on 
TTH and RH measurements, and demonstrated better reproducibility versus conventional 
in vivo assays. 
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Chapter 1  
 
         Introduction 
 
 
A validated method for determining the onset of hemostasis in vivo is necessary 
for developing effective therapeutic agents for patients with bleeding disorders such as 
hemophilia A and von Willebrand’s disease (VWD). This thesis will present a novel 
method of in vivo hemostasis assessment, Acoustic Radiation Force Impulse (ARFI)-
Monitored Hemostatic Challenge. Chapter 2.1 describes current methods for assessing 
hemorrhage in animal models and in the clinic. Weaknesses of these methods, such as 
high variance between measurements, have driven the development of ARFI-based 
techniques. A background of ultrasonic and elastographic imaging is presented in Chapter 
2.2. A discussion of the unique impact of blood on measured displacements in soft tissue 
for ARFI implementation for hemorrhage detection is contained in Chapter 2.3.  
Rate of hemorrhage and time to hemostasis are important metrics that ARFI is 
able to derive from visualized hemorrhage over time. Chapter 3 presents technical 
optimization of calculations for rate of hemorrhage (RH) and time at which hemostasis is 
achieved (time to hemostasis, TTH). Methods for RH and TTH calculations are compared 
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in Chapter 3.2 with associated in vivo results. A robust method for the removal of noise 
as discussed in Chapter 3.3. Accurate TTH and RH measurements without corruption 
from physiological noise allow for assessment of hemostasis in vivo, which may provide 
valuable information about efficacy of therapeutics. 
In vivo implementation of RH and TTH measurements in a canine model of 
hemophilia is presented in Chapter 4. Dogs are an ideal large animal model for ARFI 
Monitored Hemostatic Challenge due to similarities between bleeding phenotypes in 
healthy dogs, dogs with hemophilia A and von Willebrand’s Disease, and their human 
counterparts. The reproducibility of the imaging protocol and associated measurements 
are examined across groups after separate imaging events and within each dog. Initial 
results after inducing the expression of canine Factor VIIa (cFVIIa) are presented, as are 
results from a FVII deficient dog in Chapter 4.3.  
Validation of this hemostatic challenge is described in Chapter 5. There are no 
comparable in vivo hemostasis assays to verify that ARFI derived TTH and RH 
accurately reflect the behavior of each dog after injury. Moreover, it is necessary to 
validate this protocol before translating this research into a clinical setting. Known 
volumes of citrated blood injected into muscle tissue over known times during serial 
ARFI imaging may be a viable validation technique for ARFI derived hemostasis 
measurements. In-depth protocols are presented, along with difficulties encountered in 
accurately validating rate of hemorrhage and time to hemostasis measurements. Future 
modifications to the protocol are discussed.  
Finally, Chapter 6 discusses future directions for ARFI Monitored Hemostatic 
Challenge, including further technological developments as well as clinical and pre-
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clinical implementations. Future research is necessary to bring ARFI Monitored 
Hemostatic Challenge into the clinical realm, and focus on validation with 3D ultrasonic 
imaging techniques may be the most promising step toward clinical application of this 
technique. 
Chapter 2  
 
Hemostatic Disorders and Technological Innovation     
 
2.1 Motivation for Technology Development 
 
2.1.1 Need for Validated In Vivo Hemostasis Assay 
 
There exists a need for a validated in vivo hemostasis assay to test the efficacy 
and safety of therapeutic agents for inherited and acquired bleeding disorders. Inherited 
bleeding disorders are caused by the absence of certain plasma coagulation proteins, such 
as missing or deficient Factor VIII (FVIII) in hemophilia A and von Willebrand’s factor 
(VWF) in von Willebrand’s disease (VWD). Clotting factor replacement products can be 
introduced through intravenous infusion to reduce bleeding events [1–4]. Regular 
prophylactic use can be an effective means of decreasing the frequency of bleeding, 
allowing patients with inherited bleeding disorders to have some return to normalcy in 
their daily lives [1], [5–8]. On-demand treatments immediately relieve acute hemorrhage 
during bleeding episodes, but do not have long term therapeutic benefits seen with 
prophylactic use [9]. However, even the most effective treatments for bleeding disorders 
have associated risks and complications. Regular prophylactic use requires 
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individuals to undergo costly and time-consuming infusion procedures either in the home 
or in the clinic; frequent prophylactic use is directly correlated with a decrease in 
bleeding episodes that require treatment [8], [10]. Although these individuals may have 
reduced frequency of hemorrhage, there is still significant time, cost and energy required 
to maintain hemostatic normalcy. The most serious complication in hemostatic disorder 
management is the development of neutralizing antibodies to therapeutic clotting factors 
[11]. Immune responses can render the most effective therapeutics useless due to 
dangerous reactions [2], [10]. Complications and cost associated with current on-demand 
and prophylactic therapies have driven the development of new therapeutic agents. There 
exists a need for a validated in vivo hemostasis assay to test the efficacy and safety of 
new therapeutic agents for inherited and acquired bleeding disorders as they are 
developed. The ability to determine early bleeding, the formation of clots, and sustained 
hemostasis is necessary to demonstrate the direct effect therapeutics may have on 
individual bleeding events and overall hemostatic maintenance.  
2.1.2 Hemostatic Disorders and Current Therapies 
 
Inherited bleeding disorders such as Hemophilia A and von Willebrand’s Disease 
(VWD) arise from genetic deficiencies in plasma coagulation factors. Hemophilia A and 
B are X-linked bleeding disorders caused by mutations in the genes for Factor VIII 
(FVIII) and IX (FIX), respectively. Mild, moderate, and severe forms of the diseases are 
determined based on factor plasma levels. Levels of 1% or less are considered severe, 2-
5% are considered moderate, and 6-30% are considered mild [12]. The prevalence of 
hemophilia A is much higher than hemophilia B, with hemophilia A reported in five 
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times more patients than hemophilia B [13]. Von Willebrand’s Disease occurs about 
twice as frequently as hemophilia B [13].  
Acquired bleeding disorders typically arise after antithrombotic or antiplatelet 
therapies such as Coumadin or aspirin. In very rare cases, acquired hemophilia A occurs 
when individuals develop antibodies to intrinsic FVIII, resulting in FVIII deficiency due 
to neutralization of the clotting factor [14], [15]. Von Willebrand’s Disease can also be 
acquired, resulting in decreased functionality of VWF [16]. Both acquired hemophilia A 
and VWD are usually associated with additional complications, such as autoimmune 
disease and the use of certain pharmaceuticals.  The development of therapeutics, 
particularly for acquired hemophilia A, is driven by the same need that exists in the 
inherited bleeding disorders community; reduction of cost and increased efficacy and 
safety of therapeutics are necessary for improved quality of life in these individuals. 
Certain therapeutics, such as recombinant FVIIa, are utilized for both acquired and 
inherited bleeding disorders [6], [12], [15], [17], [18]. Overlap in treatments for acquired 
and inherited bleeding disorders renders animal models of inherited bleeding disorders 
relevant for the development of therapeutics that function globally for all hemostatically 
abnormal patients.  
Patients with severe bleeding disorders used to suffer from a reduced quality of 
life. Complications from bleeding disorders included frequent bleeding episodes, 
arthropathy, and decreased life expectancy. However, with the advent of on-demand and 
prophylactic treatments many patients are experiencing overall increased quality of life 
with reduced healthcare costs and burden [2]. On-demand FVIII infusions are a reliable 
way to quench acute hemorrhage in hemophilic patients [19]. Coagulation factor therapy 
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became widely available in the United States in the 1960s; however early concentrates 
were not used for home-care until the 1970s [1]. At this time, increased access to 
coagulation factor replacements was associated with increased risk of transmission of 
disease. Through the 1980s the transmission of hepatitis and HIV decreased quality of 
life and life expectancy for hemophiliacs; in the early 1980s 60-70% of all hemophiliacs 
in Western Europe and the US became infected with HIV from plasma concentrates [1], 
[20]. Modern advances in purification of replacement coagulation factors have reduced 
the risk of viral infection through infusions. However, current factor replacement 
therapies are not perfect; immune reactions to introduced clotting factors are a large 
problem for a significant portion of patients with clotting disorders. 
The continued development of prophylactic and on-demand therapies is driven by 
the need for highly effective and globally safe treatments for hemostatic disorders. The 
development of antibodies against clotting factors can render common therapies 
ineffective in a significant percentage of hemostatically deficient individuals. 
Alloantibodies develop in individuals with congenital and acquired hemostatic disorders; 
they neutralize introduced clotting factors, leading to continued hemostatic dysfunction 
after treatment along with severe inflammatory reactions [15], [19], [21], [22].  
Alloantibodies are hugely detrimental to the efficacy and safety of an individual’s 
therapeutic regimen. Genetic and environmental factors influence whether particular 
patients will develop alloantibodies [22], [23], [23]. Approximately 25-50% of persons 
with severe hemophilia A develop alloantibodies to FVIII, with two thirds of these 
individuals having long-term inhibitor complications [17]. Severe hemophiliacs are at 
greatest risk for developing alloantibodies due to the complete or near-complete absence 
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of circulating FVIII prior to hemostatic therapies[24]. After alloantibodies develop, the 
morbidity and mortality associated with hemophilia worsens [22], [25]. This percentage 
of the patient population is in dire need of treatments that are capable of bypassing 
immune responses without severe immunosuppression therapies.  
The developments of recombinant coagulation factors as well as gene therapy are 
promising new therapeutics for individuals with bleeding disorders and inhibitor 
formation. On-demand use of clotting factors, such as FVIII, is the first line of treatment 
against acute hemorrhage for most individuals with clotting disorders. Recombinant 
clotting factors as well as immune tolerance therapies are able to bypass FVIII 
alloantibodies in certain individuals [2], [4], [12]. Gene therapy may be able to bypass 
antibodies against FVIII while administering effective factor replacement therapy via the 
expression of high levels of clotting factors [26]. Gene therapy for the expression of 
activated FVII (FVIIa) has been able to completely reduce the need for on-demand FVIII 
infusions in a canine model of hemophilia, and may have translatable applications in 
treatment of the disease in humans. Expression of FVIIa would be a viable therapeutic 
option for individuals with and without inhibitory antibodies to FVIII [27]. Margaritis et 
al showed that partial correction of whole blood clotting time, shortening of prothrombin 
time, and complete absence of spontaneous bleeding episodes were observed in dogs that 
continuously expressed canine FVIIa (cFVIIa) [27]. However, such studies were all 
completed in canine models and would require further dose response and safety studies 
prior to translation into the clinic. Additionally, treatments such as recombinant FVIII 
(rFVIII) and gene therapy are expensive and not widely available. A major hurdle for 
future treatments of bleeding disorders is the development of inexpensive, highly 
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accessible treatment regimens through expansion of gene therapy into the clinic and the 
development of recombinant factors with extended half-lives [6].  
 
2.1.3 Current Methods for Assessing Hemostasis – Ex Vivo and In Vivo 
Technologies  
 
There is a range of methods to used determine an individual’s bleeding 
phenotype. Coagulation factor and thrombosis assays are able to aid in measuring vital 
characteristics of hemostasis, but are unable to provide in vivo measurements.  
Coagulation factor assays include aPTT, two stage, and chromogenic assays, which can 
be used to diagnose hemophilia A and monitor treatment efficacy; however, these assays 
may not fully describe bleeding phenotype or accurately reflect patient response to FVIII 
treatment and cannot be performed in vivo [28]. Whole blood assays include whole blood 
clotting time (WBCT) and thromboelastography [29]. Thromboelastography is capable of 
determining the onset of clot formation and strength of the clot over time, but is an ex 
vivo procedure requiring highly specific equipment and training [30]. Whole blood 
thrombin generation can be monitored with thrombogram-based assays ex vivo [31]. 
Although these assays are important in diagnosing deficiencies of coagulation factors, 
correlation between such assays and clinical outcome is minimal, thus driving the need 
for a validated assay to assess treatment efficacy and hemostatic status [32],[33].  
Conventional in vivo assays are currently limited in application to relevant animal 
models of hemostasis. In vivo hemostasis assays in large animal models include the 
primary saline bleeding time (1°SBT) in dogs with VWD and the primary cuticle 
bleeding time (1°CBT), gingival biopsy bleeding time, and secondary cuticle bleeding 
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time (2°CBT) in dogs with hemophilia A [34]. Primary and secondary bleeding times 
suffer from a lack of reproducibility, described in later chapters.  
Additional studies in small animal models, such as rabbits and mice, have used 
clinical coagulation factor assays [35], enzymatic assays to assess the efficacy of 
hemostatic therapies, cuticle bleeding times [36], thromboelastography [37–39], flow-
based assays [40], and tail transection bleeding time [35]. Each of the small animal 
hemostatic assays is exclusively ex vivo with the exception of cuticle and tail transection 
bleeding times. Many suffer from the same reproducibility problems as 1°CBT, 2°CBT, 
and 1°SBT in dogs. Coagulation has also been measured using ultrasonic means, 
typically based on Doppler signal intensity changes, attenuation, and integrated 
backscatter [41–44]. These methods are also exclusively ex-vivo. 
 
2.2 In Vivo Diagnostics – Ultrasonic Imaging 
 
2.2.1 Ultrasonic Imaging Principles 
 
Ultrasonic (US) imaging is a non-ionizing, non-invasive diagnostic imaging 
technique that is capable of visualizing underlying tissue morphology in real time, and 
with minimum discomfort for patients. Unlike other imaging modalities such as 
computed tomography (CT), ultrasonic imaging is free from ionizing radiation. US 
imaging systems are able to be wheeled directly to the patient’s bedside for on-demand 
imaging and diagnostics. Given these benefits, the applications for US imaging are 
widespread, from fetal to vascular imaging.  
Medical ultrasonic imaging utilizes piezoelectric imaging probes, which generate 
acoustic waves that propagate through tissues. Images are created when these waves 
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reflect off of regions of acoustic impedance mismatch, typically at tissue boundaries. As 
longitudinal waves generated by ultrasonic excitation pass through regions of differing 
acoustic impedance, a portion of the incident wave reflects at the boundary while the rest 
continues to propagate deeper into the tissue. The reflected wave, or echo, relays 
information about the location and shape of this boundary back to the imaging system, 
which is able to translate such information into real-time images. Information about the 
depth of the boundary is determined based on the assumed speed of sound in soft tissue 
of 1540 m/s and the time required to receive each echo back at the transducer face. 
Resolution of the resulting image is dependent upon the characteristics of the imaging 
probe and the emitted ultrasonic beam.  
The type of information relayed to clinicians using ultrasonic imaging varies 
based on the diagnostic imaging configuration utilized for differing applications. A-
mode, or amplitude mode, scans a single lateral region in the body and displays echoes as 
a function of depth. This particular ultrasound modality is useful for obtaining positional 
information with minimum computational requirements [45]. Brightness (B) mode 
creates two-dimensional (2D) images of tissue structures. These images are axial cross 
sections of the region being imaged created by modulating the brightness of the displayed 
information based on the amplitude of received echoes. B-mode is used frequently in 
obstetric, cardiac, and abdominal imaging [45]. M-mode, or motion-mode, collects 
information about axial displacements that vary over time, such as the motion observed in 
heart valves. Successive A-mode acquisitions create a single M-mode image [45]. 
Continuous wave (CW) and pulsed Doppler imaging is also able to provide information 
about motion, however unlike M-mode they do not track the movement of structures 
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within the body; CW and pulsed Doppler measure the velocity of moving fluids, such as 
blood. The Doppler principle allows for the measurement of velocity due to a frequency 
shift measured in reflected waves that is proportional to the velocity of scatterers [45]. 
Each of these modalities provides clinically relevant information about the morphology 
of underlying tissue structures and boundaries as well as the movement of these 
structures in normal and pathological physiologies. Other modalities of ultrasonic 
imaging are able to provide further information about underlying tissues, such as 
displaying the mechanical properties of tissues using elastography. 
2.2.2 Elastography 
 
Changes in the mechanical properties of tissue are highly dependent upon 
pathological features within the tissue structure [46–48]. Tumor growth, scar tissue 
formation, and other pathologies that result in the deposition of fibrotic tissue are stiffer 
than surrounding healthy tissues [48]. Physicians are able to manually determine the 
location of stiff lesions in tissues using palpation. However, there are several challenges 
to manual palpation, including localization of small or deep lesions that may not be 
discernible by touch. Additionally, manual palpation is highly operator dependent and 
qualitative in nature [49]. 
The need for a robust method to quantitatively determine the location and size of 
pathological lesions in tissues has driven the development of ultrasound elastography. B-
mode ultrasound is capable of determining morphological changes due to pathology; 
however, when lesions consist of tissues with the same acoustic properties as healthy 
surrounding tissues, B-mode alone is unable to distinguish lesion size and location [49]. 
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Elastography is able to supplement B-mode imaging by providing valuable data about 
changes in the mechanical properties of tissues [50–52].  
Elastographic images are made using multiple techniques to induce mechanical 
changes in tissue that elucidate differences in tissue stiffness. Elastograms display the 
elasticity of tissues based on estimated strain as a result of applied stress. Tissue 
compression is achieved by externally applying force through the use of the imaging 
transducer itself or mechanical vibrators, or through internal methods such as cardiac 
pulsation or high intensity acoustic impulses [53]. Axial strain from pre- and post-
compression images is measured using correlation-based techniques, such as cross-
correlation or Kasai’s method [50], [51]. Comparison of successive A-lines renders 
displacement measures over time, allowing elastography to track peak displacements as 
well as recovery characteristics.  
2.2.3 Acoustic Radiation Force Impulse Ultrasound 
 
Acoustic radiation force impulse (ARFI) ultrasound uses the properties of energy 
transfer to induce micrometer level displacements in underlying tissues. The transfer of 
momentum between introduced sound waves, as in ARFI imaging, and the medium 
through which these waves travel is capable of generating force on this medium [46]. 
This force is defined as, 
 
   
         
 
   
   
 
 Equation 2.1 
where F (kg/(s
2
cm
2
)) is radiation force exerted on the medium, Wabsorbed (Watts/100cm
3
) 
is the power absorbed by the medium, α (1/m) is the attenuation coefficient of the 
medium, I (W/cm
2
) is the average acoustic intensity over time, and c (m/s) is the acoustic 
speed of sound in the tissue [46]. In the case of acoustic imaging, sound waves propagate 
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through tissues in the body. Based on variations in the speed of sound and acoustic 
attenuation in tissues, Equation 2.1 relates the intensity of the acoustic field to the force 
applied. This applied force results in measurable displacements near the focal region. 
Recovery characteristics after displacement, as well as the magnitude of the displacement 
itself, are directly affected by the mechanical properties of underlying tissues. Additional 
metrics can be measured from the behavior of displaced tissue, as is discussed in later 
chapters.  
 Elastic properties of tissue can be directly measured by tracking the movement of 
shear waves after acoustic radiation force (ARF) excitation. Compressive waves, which 
propagate in the axial direction, are what induce measurable axial displacements in the 
region of excitation. However, energy transferred after ARFI excitation creates waves 
that also propagate lateral to induced axial displacements, known as shear waves. Shear 
wave velocity (SWV) is proportional to the shear modulus of tissues, as seen in Equation 
2.2, 
      √
 
 
 Equation 2.2 
where SWV (m/s) is the shear wave velocity, µ (kPa) is the shear elastic modulus and ρ 
(g/m
3
) is the density of the tissue through which the wave propagates [54].  
 ARFI displacements are measured in the region of excitation [46]. The 
progression of ARFI imaging can be seen in Figure 2.1. Initially, reference images are 
acquired using B-mode imaging to determine the baseline conditions of the tissue (not 
pictured). ARFI excitation, consisting of a high intensity acoustic impulse (~ 70 
microseconds), diplaces tissue axially (Figure 2.1). Sixty B-mode tracking pulses 
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subsequently track the resulting displacement and recovery profile of the tissue over time, 
creating a 2D matrix of displacement profiles (Figure 2.2). Parametric images are made 
from measurements of the peak displacement at each axial and lateral position over the 
2D imaging field. 
 
Figure 2.1: General method for ARFI Imaging. A high intensity acoustic impulse (red arrow) 
induces displacements in the region of excitation (blue dot). The tissue is allowed to recover, and 
characteristics such as peak displacement are measured. 
ARFI ultrasound is well suited to the application of in vivo hemostasis 
monitoring. Unlike conventional ultrasound, which is best suited for imaging underlying 
morphology but does not take into account changes in mechanical properties, ARFI is 
able to visualize localized regions of stiffening or softening that may be associated with 
hemorrhage. ARFI is also advantageous compared to transient elastography due to the 
behavior of fluids after ARFI excitation and after elastic deformation. Hemorrhage 
isolation using conventional elastography and ultrasound is complicated by intersecting 
frequency information and low amplitude signal from blood versus soft tissues [55], [56]. 
The behavior of hemorrhage after ARFI excitation is discussed further in Chapter 2.3. 
2.3 Hemorrhage Detection Using ARFI Techniques 
 
Clinical onset of hemostasis is currently determined by visual inspection of 
bleeding sites or hematoma formation. Although this may be a reliable method for 
hemostatically normal individuals, visual inspection fails to identify subcutaneous 
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bleeding that may continue to occur after injury in individuals with inherited or acquired 
bleeding disorders [57]. This is typically due to clot formation at the skin surface while 
bleeding continues at the site of vascular injury below [58].  
ARFI ultrasound is a viable alternative to visual inspection to determine the onset 
of hemostasis. Previous work has shown that ARFI ultrasound is capable of inducing 
streaming in human carotid arteries and fluid filled lesions [59], [60]. Sonorheometry 
measures blood coagulation times using ARF methods by measuring the mechanical 
properties of developing clots ex vivo [61]. ARFI specifically has been shown to be a 
relevant technique for monitoring the onset of hemostasis after cardiac catheterization of 
the femoral artery [62] and in canine models of hemophilia A and von Willebrand’s 
disease [34], [63]. This body of previous research supports further development of ARFI 
as a noninvasive tool to assess hemostasis in vivo. 
2.3.1 Impact of Hemorrhage on ARFI Measured Displacement and Correlation 
 
The presence of extravasated blood after injury to a vessel has distinguishable 
effects on ARFI induced displacements. Behler et al. [58] found that ARFI-induced peak 
displacements were larger in regions of pooled hemorrhagic blood in soft tissues than in 
surrounding soft tissues alone. Importantly, recovery characteristics in the hemorrhagic 
blood were highly decorrelated, suggesting that pooled blood did not elastically recover 
from ARFI-induced displacement.  
In the second of their two-part series, Behler et al. [62] further elaborated upon 
the effect of extravasated blood on ARFI-induced displacement profiles and correlation. 
Soft tissue was expected to recover from ARFI excitation after approximately 2 ms; 
however hemorrhagic blood and luminal blood do not exhibit this recovery behavior. 
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Hemorrhage takes longer to recover, while luminal blood flows with cardiac pulsation. 
The authors demonstrated that due to this behavior, luminal blood decorrelated quickly 
relative to hemorrhagic blood, which decorrelated faster than soft tissue [64].  
The decorrelation found in hemorrhagic and luminal blood is visible as regions of 
high variance toward the end of associated displacement profiles. Variance in the 
displacement estimate, colloquially termed “jitter,” occurs with signal decorrelation in 
ARFI displacement tracking measurements. Jitter is defined as: 
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where fc is the center frequency of the imaging transducer, T is the kernel size used for 
displacement estimation, B is the fractional bandwidth of the imaging transducer, ρ is the 
correlation coefficient between the reference and tracking lines, and SNR is the signal-to-
noise ratio [65]. As signal decorrelates a proportionate increase in the amount of jitter 
occurs. In Field II simulations, Palmeri et. al [65] and McAleavey et al. [66] confirm that 
jitter increases with displacement magnitude and lower correlation coefficient. This 
behavior is directly seen in regions of extravasated blood, in which displacements are 
higher than in soft tissue and tracking decorrelates with localized blood pooling 
compared to regions of soft tissue. Pooled blood responds to ARFI displacement by 
streaming, which results in increased displacement estimation error [56], [66]. Figure 2.2 
illustrates low correlation values in a single pixel identified as hemorrhage compared to a 
single pixel identified as soft tissue. Note that the pixel identified as hemorrhage has a 
consistently lower correlation coefficient over the duration measured compared to soft 
tissue, which has a correlation coefficient of very nearly 1. Moreover, the maximum 
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displacement measured in the hemorrhagic pixel is approximately ten times greater than 
in the soft tissue pixel.  
 
Figure 2.2: Correlation values measured in soft tissue and hemorrhage over ARFI observation 
period. Note that the correlation in the hemorrhagic pixel is generally lower than the correlation 
in soft tissue. Additionally, the peak displacement measured in the hemorrhagic pixel was 
approximately 10 times larger than the peak displacement measured in the soft tissue. 
Increased jitter in displacement tracking is evident after soft tissue has 
presumably recovered from ARFI excitation after approximately 2 ms.  Differences in the 
amount of displacement tracking error between soft tissues, pooled extravasated blood, 
and luminal blood displacements is amplified using a second derivative operator. 
Luminal blood is expected to have the highest displacement estimation variance after 
applying the second derivative operator, indicative of a high level of jitter in the 
displacement profile. Conversely, soft tissue is expected to have the lowest displacement 
estimation variance after the second derivative operator, suggesting that soft tissue has 
fully recovered after 2 ms with minimum jitter present in the displacement profile [55], 
[63].  
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2.3.2 Methods for Identifying Hemorrhage Using ARFI Ultrasound 
 
Building upon previously discussed effects of hemorrhage on displacement 
profiles and correlation measurements, a method for identifying hemorrhage has been 
developed. As described by Scola et al. [63] and depicted in Figure 2.3, luminal blood, 
extravasated blood, and soft tissue are distinguishable using ARFI ultrasound. Figure 2.3 
is specific to the protocol used to acquire much of the data presented herein, in which 
injury is caused to a vein using a large gauge needle. Bleeding is observed after injury, 
and hemorrhage is identified using the algorithm depicted in Figure 2.3. An ultrasonic 
imaging probe is placed on the skin surface, and displacement profiles are obtained from 
a 2D field of view. As soft tissue is expected to have fully recovered by approximately 4 
ms, all data prior to this time is discarded. The second derivative of ARFI induced 
displacements from 4 ms onward is obtained (indicated by the red squares on the 
displacement profiles in Figure 2.3), magnifying the presence of displacement estimation 
variance, or jitter, in the displacement profile. The second derivative operator is a high 
pass filter that amplifies variance in the displacement estimation. Notice that the second 
derivative of displacement in the lumen has much larger amplitude than in soft tissue, 
while hemorrhage is somewhat in the middle. The variance of this measurement is then 
taken, resulting in a high variance measure in the lumen, low variance in soft tissue, and 
moderate variance in hemorrhage. Thresholding on the variance of the second derivative 
of displacement after soft tissue recovery as well as on the peak displacement of soft 
tissue distinguishes regions of suspected hemorrhage.  
The hemorrhagic area can be measured by multiplying the pixel size by the 
number of identified extravasated blood pixels. Serially acquired ARFI is used to obtain a 
 20 
 
time series of data points for which hemorrhagic area can be calculated. Figure 2.4 
illustrates a resulting hemorrhagic area vs. time curve, in which each point on the curve 
was found by calculating the area of extravasated blood identified at several serially 
acquired time points. Hybrid B-mode/ARFI images are created, coloring identified pixels 
red (Figure 2.4, bottom row). A baseline image taken prior to vessel injury illustrates the 
lack of detected hemorrhage at this time point. This suggests that ARFI Monitored 
Hemostatic Challenge selectively visualizes hemorrhage since no identified hemorrhage 
pixels are present prior to vessel injury. 
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Figure 2.3: Method of hemorrhage detection using acoustic radiation force impulse (ARFI) 
Monitored Hemostatic Challenge. (a) The transducer is positioned on the hind limb. Two needles 
are placed above the vessel of interest: a small needle positioned under ultrasonic guidance, and a 
larger needle used to cause injury to the vein. (b) The vessel lumen (left), regions of extravasated 
blood and soft tissue (center), and muscle and soft tissue (right) have different recovery 
behaviors. These are particularly evident long after the peak displacement. Variations in the 
displacement profile after 4ms (boxed) time are amplified using the second time derivative 
operator (c). Inspection of the variance of the second time derivative of displacement reveals 
relationships between the vessel lumen, hemorrhage area, and soft tissues. Hemorrhage can then 
be distinguished by utilizing upper and lower thresholds on the variance measure (d). 
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Figure 2.4: Resulting normalized area vs. time plot for ARFI Monitored Hemostatic Challenge. A 
baseline ARFI frame prior to vessel injury (top left) along with serial ARFI frames (bottom row) 
in a naïve hemophilia A dog were acquired. Hemorrhagic pixels were identified in each of the 
four ARFI frames and colored red.  The normalized area of hemorrhage in each frame is 
calculated and plotted against time (top right). This dog with hemophilia A was infused with 
cFVIII to 10% after 30 minutes. 
Chapter 3  
 
Optimization of Measurements from ARFI Monitored Hemostatic Challenge 
 
 The bulk of work presented in this thesis involves technical optimization of the 
ARFI-monitored hemostatic challenge. The ability to noninvasively detect hemorrhage 
using ultrasonic imaging allows for continuous measurement of metrics such as the rate 
of hemorrhage and the time required to achieve hemostasis. Two methods of calculating 
the rate of hemorrhage are presented and compared, as are two methods for measuring 
the time to hemostasis. Additionally, a spatial clustering method used to remove noise 
beneath the focal depth is described.  
 
3.1 Imaging Parameters and Methods 
 
All dogs were treated following the standards outlined in the Guide for Care and 
Use of Laboratory Animals (National Institutes of Health publication No. 85-23). All 
protocols were approved by the University of North Carolina at Chapel Hill Institutional 
Animal Care and Use Committee. All dogs were maintained and bred by the Francis 
Owen Blood Research Laboratory at the University of North Carolina at Chapel Hill. 
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Dogs were imaged on two occasions separated by a number of months to allow 
each dog to recover after the procedure. Prior to imaging, dogs were fully anesthetized 
with approximately 2% isoflurane. Blood pressure, heart rate, oxygen saturation, and core 
body temperature were monitored throughout the procedure.  
Dogs were situated in a prone position for the duration of imaging. The hind limb 
was shaved and prepped with an aseptic method. To reduce motion caused by the dog’s 
breathing or fluctuations in the dog’s response to anesthesia, the hind limb was tethered 
to the examination table. A stereotactic clamp held the ultrasound transducer above a 
peripheral vein of approximately 2mm diameter. A standard hemostatic challenge was 
performed as outlined in Scola et. al [34]. Briefly, utilizing ultrasonic image guidance a 
22-gauge guide needle was placed superficially to the vein of interest. Continuing using 
ultrasonic image guidance, a small incision was made at the site of skin puncture through 
which a 12-gauge needle was steered to puncture the hind limb muscle and vein (Figure 
3.1). The vein was punctured five sequential times, and the 12-gauge needle was then 
rotated five times to ensure injury to the vessel. ARFI data and spatially matched  
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B-mode frames were acquired before the puncture as a baseline measurement, every 
minute for 15 minutes after the puncture, every two minutes from 15-25 minutes, and 
every 5 minutes from 25-100 minutes after puncture. Imaging ended after a total period 
of 100 minutes. The standard hemostatic challenge was completed on a variety of dogs 
exhibiting different bleeding phenotypes, outlined in Table 3.1. Each normal dog, dog 
with naïve hemophilia A, and dog treated with infused FVIII or gene therapy to express 
canine FVIIa (cFVIIa) was imaged twice for reproducibility measures, with imaging 
events separated by a minimum of 2 months. Six phenotypically normal dogs were used 
as controls. Eight dogs with naïve hemophilia A were monitored for 30 consecutive 
minutes of bleeding, after which time they were administered an infusion of canine FVIII 
Figure 3.1: Placement of the imaging transducer and needles 
during ARFI monitored hemostatic challenge. The 22-gauge guide 
needle was used to position the 12-gauge injury needle at the 
appropriate vessel site. The vein was approximately 2 mm in 
diameter at a depth of 25 mm.  
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(cFVIII) to approximately 10% activity followed by an additional 70 minutes of ARFI 
monitoring. Administration of cFVIII for these particular dogs directly combatted the 
formation of large hematomas caused by excessive bleeding in hemophiliacs. Four naïve 
hemophilia A dogs underwent gene therapy to express cFVIIa at 1.3-2 µg/mL [27]. Gene 
therapy is a potential prophylactic treatment for hemophiliacs [26], [67], [68], while 
infusion with cFVIII is an on-demand treatment [2]; inclusion of both treatments in the 
experimental design allows for insight into the benefits and drawbacks of on-demand vs. 
prophylactic therapies.  Six dogs with naïve von Willebrand’s Disease (VWD) were 
imaged before and after use of prophylactic von Willebrand’s Factor. Each of these dogs 
was imaged in a single event.  
Table 3.1: Detailed breakdown of bleeding phenotypes imaged in these studies, the number of 
dogs imaged in each phenotype, and the number of imaging sessions for each dog. All 
phenotypes, with the exception of von Willebrand’s Disease and von Willebrand’s Disease with 
therapeutic von Willebrand’s Factor, were imaged twice for reproducibility. 
Bleeding Phenotype N 
Number of  
Imaging Sessions 
Normal 6 2 
Naïve Hemophilia A 8 2 
Naïve Hemophilia A +  
Infused cFVIII 
8 2 
Naïve Hemophilia A  
Expressing cFVIIa 
4 2 
Naïve von Willebrand’s Disease 6 1 
von Willebrand’s Disease +  
Infused von Willebrand’s Factor 
6 1 
 
ARFI imaging was performed using a Siemens SONOLINE Antares™ ultrasonic 
imaging system equipped for research purposes (Siemens Medical Solutions USA, Inc., 
Ultrasound Division) and a VF7-3 linear array transducer. The ARFI beam sequence used 
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for this application consisted of two conventional, two-cycle A-lines, followed by a 300-
cycle (70 μs) ARFI excitation impulse centered at 4.21 MHz. The excitation impulse had 
an F/1.5 focal configuration. ARFI excitation was followed by a tracking ensemble of 60 
(6 ms) conventional A-lines at a center frequency of 6.15 MHz and pulse repetition 
frequency of 11 kHz. The entire excitation-tracking ensemble was repeated in 40 lateral 
locations over a 2.1 cm lateral field of view resulting in 0.53 mm spacing, as illustrated in 
Figure 3.2. The focal depth for imaging was positioned at the proximal venous wall, 
which was typically located between 20 and 25 mm in depth. A 2 cm thick standoff pad 
was utilized when the hind limb was too lean to locate a vessel at the appropriate depth; 
the standoff pad was not necessary except when imaging dogs with von Willebrand’s 
Disease, as they are a smaller breed.  
 
Figure 3.2: ARFI beam sequence acquired in 40 lateral locations spanning a 2.1 cm lateral field of 
view. Light blue arrows show two reference A-lines prior to ARFI excitation. Red arrows indicate 
the ARFI excitation, while dark blue arrows are the tracking ensemble of 60 conventional A-lines 
after ARFI excitation.  
   
Acquired RF data were transferred to an off-line computational workstation for 
processing with a commercial software package (Matlab R2010a, The MathWorks Inc., 
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Natick, MA). One-dimensional (1-D) axial displacements were estimated along each 
acquired excitation-tracking ensemble using cross-correlation with a 1.5 λ kernel, an 
interpolation factor of 4, and a search window length of 80 μm [69]. A linear filter 
applied to the measured ARFI displacement profiles was utilized to reject physiologic 
motion artifacts [70]. Localized regions of hemorrhage caused by needle puncture were 
isolated using custom software outlined in Chapter 2.3. The area of hemorrhage found in 
each ARFI acquisition was estimated by multiplying the number of identified 
hemorrhage pixels by the pixel area, approximately 0.01 mm
2
. Plots of area identified as 
hemorrhage vs. time were created for each dog.  
To determine whether ARFI excitation was required or whether physiological 
motion caused by the pulsatile motion of blood was sufficient for hemorrhage detection, a 
no-push sequence was utilized. The same sequence as described previously was used 
without the ARFI excitation with identical motion tracking and hemorrhage isolation. As 
seen in Figure 3.3, two sequential, spatially matched ARFI frames show that the ARFI 
excitation is necessary for hemorrhage visualization. The imaged formed without ARFI 
excitation did not detect any hemorrhagic pixels (Figure 3.3b); whereas the imaged 
formed with the ARFI excitation (Figure 3.3a) found a region of localized hemorrhage 
above the upper vessel wall.  
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Figure 3.3: Comparison between hemorrhage detection with different beam sequences. The push 
sequence used an ARFI excitation impulse followed by 60 conventional, tracking A-lines (a). The 
no-push sequence did not have the excitation impulse (b) for hemorrhage detection. Pixels 
identified as hemorrhage are colored red.  
 Normalized plots of detected hemorrhage area vs. time were created for each dog 
imaged. From these plots time to hemostasis and hemorrhage rate were measured. 
Representative plots in Figure 3.4 show the different bleeding profiles for different 
phenotypes. The bleeding profiles created using the ARFI Monitored Hemostatic 
Challenge agree with expected behaviors for each phenotype. Normal dogs will bleed 
quickly and clot quickly, while naïve hemophilia A results in an extended, slow bleeding 
profile without any discernible plateau in the amount of hemorrhage detected prior to 
treatment with infused cFVIII at 30 minutes. Hemophilia A after gene therapy to express 
cFVIIa begins to resemble a normal phenotype, with a tapering in the amount of 
hemorrhage over time. VWD and VWD + VWF illustrate the prophylactic effects of 
administered VWF. Naïve VWD bleeds extensively initially, and may saturate the 
available field of view for hemostatic assessment. Compared to naïve VWD, prophylactic 
administration of VWF prior to injury results in a reduction of initial bleeding rate with 
less measured hemorrhagic area over time.  
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Measurements of interest obtained from measured hemorrhagic area vs. time plots 
include the rate of hemorrhage (RH) in mm
2
/min and the time necessary to achieve 
hemostasis (time to hemostasis, TTH). The remainder of this chapter will discuss two 
algorithms for the calculation of RH followed by two algorithms for the calculation of 
TTH, as well as examples of in vivo implementation. 
 
Figure 3.4: Typical normalized hemorrhagic area vs. time plots for five bleeding phenotypes 
investigated here: normal (a), naïve hemophilia A treated with infused cFVIII after 30 minutes 
(b), naïve hemophilia A expressing cFVIIa (c), naïve VWD (d), VWD + VWF (e). Each 
phenotype has a specific bleeding profile that is reflected in the area vs. time plots. 
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3.2 Calculation of Rate of Hemorrhage 
 
3.2.1 Discrete, Non-Overlapping Windows  
 
The rate of hemorrhage is defined herein as the change in measured hemorrhagic 
area over time for purposes of assessing hemostatic normalcy or dysfunction. The first 
algorithm developed for this measurement utilized discrete, non-overlapping 10-minute 
intervals over which the slope of the detected hemorrhage area vs. time plot was 
measured (Figure 3.5) [63]. Hemorrhage area was divided into 10 discrete, non-
overlapping 10-minute intervals. The measured hemorrhage area in each interval was fit 
using a piecewise linear-least square approximation. The slope of each fit line can be 
used as a direct measurement of hemorrhage rate.  
Utilization of discrete 10 minute intervals was advantageous in noisy datasets, in 
which outliers negatively affect rate measurements. Effects caused by outliers would be 
amplified if rate were calculated based on the instantaneous time derivative at each point. 
Measuring the slope over a ten minute period has a slight averaging effect on the data by 
fitting a best fit line through the center of the data, thus negating any extreme outliers and 
their influence on rate measurements. Assuming that the majority of hemorrhage is 
located within the ARFI imaging plane and field of view, the general trend of 
hemorrhage is accounted for in each ten minute segment; however, minute-to-minute 
variations in bleeding behavior are minimized using this method due to the 
aforementioned noise reduction over the observed time period.  
A disadvantage of this method is the small number of resulting rate values from 
each imaging session. Over a given 100 minute acquisition period, only 10 rates can be 
measured. As a result, very slight changes in the bleeding profile do not have a large 
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impact on the rate measurement. Typically, these slight changes in the bleeding profile 
should not drastically alter the rate measurement. However, fluctuations in the measured 
hemorrhagic area may be indicative of the breakage of weak clots, and therefore provide 
important information about the stability of the clot over time. This is particularly evident 
when inspecting the bleeding profile of naïve Hemophilia A expressing cFVIIa at 1.3 
μg/ml (Figure 3.6). When compared to naïve Hemophilia A without treatment (Figure 
3.4b), the genetic therapy drastically reduces the amount of bleeding. However, 
fluctuations seen in the raw data, shown in red circles, in Figure 3.6 and Figure 3.4c may 
provide insight into the fragile nature of the forming clot in this particular dog after 
therapy. Instantaneous changes in measured hemorrhagic area over time are minimized in 
each fitted line segment, thus removing high frequency noise from the bleeding profile 
along with any relevant physiological data the high frequency information may carry.  
 
Figure 3.5: First algorithm for the measurement of the rate of hemorrhage in a representative 
normal dog. Ten minute intervals are fit to the measured data points (red circles) using a linear 
least-squares regression approximation (blue line). The slope of each line segment is the 
measured rate of hemorrhage (mm
2
/min).  
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Figure 3.6: Bleeding profile for a dog with naïve Hemophilia A expressing cFVIIa at 1.5 μg/ml. 
The slope of each fit line over ten minutes is calculated as the rate of hemorrhage. The data points 
acquired during the imaging session (red circles) fluctuate intensely between 40 and 70 minutes. 
3.2.2 Sliding Window 
 
The second algorithm was developed to provide minute-by-minute information 
about the hemorrhage while minimizing the effect of noise in the signal. A sliding 
window of an empirically determined length was used rather than discrete, non-
overlapping ten minute segments. Three, five, and ten-minute windows were chosen for 
use in this method with one set of results shown in Figure 3.7. To create rate of 
hemorrhage vs. time plots, the initial window begins at the first point on the hemorrhage 
area vs. time curve (t = 0). A linear-least square line is fit through the number of 
subsequent points as indicated by the window length, seen as small line segments plotted 
in Figure 3.7. The slope of this line directly correlates to the first point on each rate vs. 
time curve in Figure 3.8. The window then shifts through the data in steps of one, fitting a 
linear-least square line after each shift. The slopes of these fit lines form the remainder of 
the rate vs. time curve (Figure 3.8).  
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The sliding window method with a kernel size of 10 minutes has several 
advantages over the static 10 minute window calculations. More detail about the transient 
rate of hemorrhage over time is available when calculating rate with the sliding window. 
Rather than measuring 10 unique rates over a 100 minute acquisition, this method 
measures 90 individual rates corresponding to every position over which the window 
slides. This provides valuable insight into the fluctuations of bleeding profiles. However, 
depending on the window length utilized, rate measured using the sliding window 
method is vulnerable to noise or high frequency information in the signal.  
A window length of ten minutes was empirically determined for analysis of the 
100 minute observation period utilized in this protocol. The use of a ten minute kernel 
length provided significant noise reduction without excessive removal of valid high 
frequency information in the bleeding profile. Unfortunately, noise and natural 
oscillations in bleeding profiles were not always discernible, resulting in the reduction of 
noise at the expense of valid data when using large kernel sizes. Small kernels resulted in 
rate measurements that resemble instantaneous rate measurements, such as those found 
by looking at the time derivative of the bleeding profile, but at the expense of noise 
reduction. Figures 3.7 and 3.8 demonstrate the effect of 10, 3 and 5 minute kernels on 
rate measurements. 
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Figure 3.7: Measured hemorrhagic area vs. time plots for a representative normal dog. Data 
points measured during the imaging session (red circles) are fit using a linear least-square 
approximation over a ten minute sliding window (blue lines). The slope of each fit line is 
measured as the average rate over the ten minute window. The kernel length for each sliding 
window is 10 minutes (top), 5 minutes (bottom left), and 3 minutes (bottom right). 
 
Figure 3.8: Rate of hemorrhage vs. time calculated for the bleeding profiles in Figure 3.7. Each 
point on the rate vs. time curve is calculated as the slope of the fitted line over each time step in 
the blood area vs. time plot. The kernel sized for rate calculations are 10 minutes (top), 5 minutes 
(bottom left) and 3 minutes (bottom right). 
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3.3 Calculation of Time to Hemostasis 
 
The time to hemostasis measurement pinpoints the cessation of bleeding after 
injury in each of the bleeding phenotypes examined herein. Two separate methods were 
utilized for TTH measurements: time necessary to reach 75% of the maximum 
hemorrhagic area measured, and time at which the rate of bleeding approaches zero or 
becomes negative for 5 consecutive minutes.  
3.3.1 Time to Hemostasis Based on Measured Hemorrhagic Area 
 
The time to 75% of maximum measured hemorrhagic area provides information 
about the time at which bleeding substantially slows. It is found by locating the time at 
which detected hemorrhage area reaches a maximum on the area vs. time plot, such as 
those presented in Figures 3.5, 3.6, and 3.8. The algorithm then searches from t = 0 to the 
time at which this maximum occurs, t = tmax, to determine the first point where the 
detected hemorrhage area is equal to 75% of the maximum, denoted as the time required 
to achieve hemostasis [34], [63]. Time to 75% of maximum is indicated in Figure 3.9 by 
the vertical lines intersecting the y-axis at 0.75 mm
2
 and the x-axis around 13 minutes. 
Previously reported results using this measurement of time to hemostasis [34], [63] 
successfully demonstrated different TTH based on bleeding phenotype. Naïve hemophilia 
A resulted in significantly longer TTH than healthy dogs. However, the measurement of 
75% of maximum is somewhat arbitrary. This metric corresponds to the time necessary to 
have a significant reduction in the rate of hemorrhage; yet, as is evident in Figure 3.9, the 
TTH denoted by the red lines does not necessarily align with a cessation in bleeding. The 
measured hemorrhagic area for this particular dog continues to increase even after 
hemostasis is presumably achieved. TTH based on measured area of hemorrhage is able 
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to provide a single, consistent metric, while determining hemostasis using bleeding rate 
may detect multiple instances of the onset of hemostasis, as described in Chapter 3.3.2.  
 
Figure 3.9: Time to hemostasis as measured using the time to 75% of the maximum measured 
hemorrhagic area in a representative normal dog. TTH is approximately 13 minutes, as indicated 
by the horizontal red line beginning where the area is equal to 0.75 mm
2
 and intersecting the time 
axis at the measured TTH.  
 
3.3.2 Time to Hemostasis Based on Rate of Hemorrhage 
 
An alternate method for determining the time to hemostasis is based on 
characteristics of the rate measurement. Rate of hemorrhage is first calculated using the 
10 minute sliding window technique discussed in Chapter 3.2.2. Based on RH 
measurements, hemostasis is considered to be achieved when the rate approaches zero or 
becomes negative for at least 5 consecutive minutes. This would imply that the area of 
detected hemorrhage remains constant or decreases over time, presumably from the 
cessation of blood flow to the region. Importantly, hemostasis may be achieved and lost 
multiple times after injury. A typical marker of hemophilia A is the formation of weak 
clots after injury [30], [71], which may result in multiple instances of continued bleeding 
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as the clot breaks and reforms after injury. Measuring TTH using the rate calculation 
allows for the assessment of natural fluctuations in hemostatic status by providing 
information about the onset and duration of hemostasis associated with thrombus 
formation. 
Figure 3.10 illustrates the concept of clot formation and breakage over time and 
the effect this has on TTH measurements. Data shown were acquired from a single dog 
with hemophilia A that expressed cFVIIa at 1.3 μg/ml. TTH measured using 75% of 
maximum would find that this individual dog achieves hemostasis after approximately 27 
minutes. However, from the plot of measured hemorrhagic area vs. time it can be seen 
that there are multiple instances where the measured area plateaus or decreases over time, 
then begins increasing again. Plateaus in hemorrhagic area occur around 10, 35, and 75 
minutes. Calculating TTH based on zero or negative rate of hemorrhage directly 
corresponds to regions in the area vs. time plot during which bleeding is decreasing or 
stopping. Inspection of the measured rate of hemorrhage vs. time plot shows that rate 
approaches 0 mm
2
/min around 10 to 15 minutes, the time of the first plateau in 
hemorrhage area. As the area begins increasing again, the rate becomes more positive. A 
second plateau in measured area occurs around minute 35, at which point the rate 
becomes negative for 5 to 10 minutes. This is indicative of formation of a weak clot, 
followed by breakdown of the clot and continued bleeding.  
For consistency, initial times at which rate is equal to or less than zero for a 
period of at least 5 minutes are reported as time to hemostasis. TTH for the particular 
example in Figure 3.10 is measured as 37 minutes, the first point at which rate is equal to 
or less than zero for a five minute period. Bleeding may continue beyond this time point, 
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resulting in a final TTH measurement much larger than the initial TTH reported. 
However, variations in the bleeding profile of most dogs do not sufficiently taper over the 
100 minute observation period due to noise in the measured signal or bleeding that 
restarts at the site of injury. Reporting the first time at which rate is equal to or less than 
zero for a five minute period provides a more robust measurement for differentiation 
between bleeding phenotypes in vivo.     
 
Figure 3.10: Measured hemorrhagic area (left) and calculated rate of hemorrhage (right) from a 
single hemophilia A dog expressing canine FVIIa at 1.3 μg/ml. The rate was calculated using a 
sliding window of ten minutes across area vs. time data. The dotted line on the rate plot indicates 
a rate of 0 mm
2
/min. TTH is calculated as 37 minutes. 
 
3.4 Spatial Clustering to Remove Noise 
 
Noise can be introduced into measurements of hemorrhage area by pixels that 
may satisfy thresholding criteria but do not contain extravasated blood. Noise has a 
similar behavior as blood within the lumen or pooled in soft tissue in that it has a high 
amount of displacement tracking error and therefore high variance of the second 
derivative of displacement. As a result, noisy pixels can be mistaken for hemorrhagic 
pixels.  This phenomenon is particularly evident outside the region of the focal depth, 
where the signal to noise ratio (SNR) is lower than within the focal depth. Decreased 
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SNR causes an increase in the measured jitter, thus causing these pixels to satisfy the 
thresholding criteria used to distinguish hemorrhage. To combat erroneous identification 
of noise pixels as hemorrhage, a spatial clustering method was implemented to remove 
data below the focal depth.  
Typically, ARFI imaging is focused on or just above the near vessel wall so 
visualization of hemorrhage above the vessel can be properly identified. There is always 
a possibility of blood pooling beneath the vessel due to injury to the lower vessel wall or 
blood flowing around and below the vessel after injury. However, protocols used for all 
experiments presented in this thesis consistently utilized a focal depth above the vessel of 
interest. Expanded depth of field of ARFI measurements will allow future studies to 
observe above and below the injured vessel, which will further improve removal of 
falsely identified hemorrhage pixels. Spatial clustering for this application focused on 
removal of identified noise pixels above and below the focal depth, typically resulting in 
the removal of pixels within and below the vessel lumen. 
The spatial clustering technique implemented relies on the creation of a reliable 
mask to remove false positives in the image. Initially, a binary mask consisting of all 
zeros of dimensions identical to lateral and axial sizes of the image data is created. 
Threshold values of the variance of the second derivative of displacement (VSDD), 
previously described in Chapter 2.3.3, are found. The natural logarithm of VSDD is 
plotted on a histogram, resulting in a plot containing three unique curves. Each curve on 
the histogram directly corresponds to tissues of interest: soft tissue, luminal blood, and 
hemorrhage. Soft tissue is expected to have the lowest VSDD compared to luminal blood 
and hemorrhage. This is confirmed by the curve specific to soft tissue on the histogram, 
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which contains the smallest values. The curve corresponding to luminal blood has the 
largest values, and hemorrhage is intermediate between the soft tissue and luminal blood 
curves. The exponential value of where these three intersect on the histogram becomes 
the lower and upper threshold values for hemorrhage detection, shown graphically in 
Figure 3.11. The green circles on the experimentally derived histogram data indicate 
points chosen as lower and upper thresholds for hemorrhage identification. 
 
Figure 3.11: Determination of lower and upper threshold values for hemorrhage detection. The 
histogram of the natural log of variance of the second derivative of displacement values contains 
three distinct curves, corresponding to luminal blood (blue), hemorrhagic blood (purple), and soft 
tissue (red). The green dots indicate the lower and upper threshold values, found at the 
intersection of each of these curves. The green dots on the histogram on the right indicate the 
lower and upper thresholds for this dataset.   
After determination of the lower and upper thresholds for hemorrhage detection, a 
mask was made of pixels that do not satisfy the hemorrhagic threshold criteria. Pixels that 
contained VSDD values less than the lower threshold were identified; these pixels 
correspond to soft tissue structures in the image, particularly to the vessel walls. A second 
threshold was then applied that found all pixels with peak displacements less than the 
identified peak displacement threshold for extravasated blood, thus selecting for pixels 
that should not contain any luminal or extravasated blood. Pixels that satisfy both the 
VSDD and peak displacement criteria are set equal to 1 in the binary mask (Figure 
3.12.1). The resulting mask has large regions equal to 1 where pixels have values less 
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than the lower threshold of both peak displacement and VSDD, effectively isolating 
pixels located in the vessel walls along with noise in the near field. Near field noise is 
removed by setting the first 5 mm of the binary mask to zero (Figure 3.12.2). Vessel wall 
pixels are easily identified due to the lack of blood pooling in the vessel wall itself. All 
pixels containing either luminal or hemorrhagic blood surround the vessel wall, but blood 
does not accumulate inside the vessel wall. Additionally, the vessel wall is highly elastic 
and therefore exhibits a lower magnitude displacement after ARFI excitation than 
surrounding blood pixels. Low displacement values combined with low VSDD make the 
vessel wall an ideal structural marker for this spatial clustering technique.  
Spatial clusters of pixels equal to one are then sorted by size. The largest cluster 
of pixels corresponds to the upper wall of the vessel, evident as a white band across the 
image in Figure 3.12.2. The algorithm then moves laterally across the field of view, 
setting all pixels below the uppermost pixel in the vessel wall to zero, and all pixels 
above that position to one (Figure 3.12.3). This mask is then applied to data when 
determining which pixels contain extravasated blood. Removal of falsely identified pixels 
is shown in Figure 3.13. Without application of the lumen mask, pixels within and below 
the vessel are identified as hemorrhage. These can have a slight effect on measured 
hemorrhagic area and rate of hemorrhage, and are therefore removed to ensure robust 
measurements.  
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Figure 3.12: Spatial clustering technique to remove falsely identified hemorrhagic pixels from 
within and below the vessel lumen. (1) Pixels with peak displacement values and variation of the 
second derivative of displacement values below the lower thresholds are set equal to 1, while all 
other pixels are set equal to zero. (2) The first 5 mm of the image are removed as noise in the near 
field. (3) All pixels below the upper vessel wall, located in the white band in the center of (2), are 
removed. All pixels above the upper vessel wall are kept for identification of hemorrhagic pixels. 
 
Figure 3.13: Application of the spatial clustering technique to remove falsely identified 
hemorrhagic pixels from within and below the vessel lumen. Without the application of a lumen 
mask (left), noisy pixels below the actual hemorrhage can distort measured hemorrhagic area and 
rate of bleeding. Falsely identified pixels are removed after application of the lumen mask using 
the spatial clustering technique (right).  
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Chapter 4  
 
In Vivo Implementation of ARFI Monitored Hemostatic Challenge 
 
4.1 Effect of Bleeding Phenotype on Time to Hemostasis and Rate of Hemorrhage 
 
Previously reported time to hemostasis and rate of hemorrhage indicate that 
bleeding phenotype has a strong effect on hemostatic metrics. Rate of hemorrhage and 
time to hemostasis were calculated for each of the dogs imaged using discrete, non-
overlapping windows and time to 75% of maximum measured hemorrhagic area, 
respectively. Significance was assessed using a linear mixed-effect model and cox 
proportional hazard regression with correlated observations. Both methods accommodate 
repeated measurements in the data, while the cox proportional hazard regression is used 
to compare hemophilia A TTH measurements (reported as greater than 30 minutes) with 
TTH from other phenotypes.  
Measured time to hemostasis in naïve hemophilia A dogs was significantly 
different from normal dogs (p < 0.0015). Treatment with infused FVIII to 10% reduced 
TTH compared to naïve states, bringing measurements for hemophilic dogs into the 
normal range (p < 0.8). Dogs with hemophilia A expressing cFVIIa had reduced TTH 
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values within the normal range as well (p < 0.79). TTH did not seem affected in naïve 
VWD and treated VWD with prophylactic infusion of VWF, with no significant 
differences from normal. The rate of hemorrhage was significantly elevated in VWD 
dogs compared to normal (p < 0.0000038). After treatment with prophylactic VWF the 
rate of hemorrhage was brought within normal range (p < 0.77). Additionally the rate of 
hemorrhage is slightly increased in naïve hemophilia A compared to normal (p < 0.015), 
which is corrected with on-demand and prophylactic treatment. These results are shown 
in Table 4.1 
Table 4.1: Rate of hemorrhage and time to hemostasis measurements for each bleeding phenotype reported 
as mean ± standard deviation. Rate of hemorrhage was measured using discrete, non-overlapping windows. 
Time to hemostasis was measured as the time to 75% of maximum hemorrhagic area in each dog after each 
imaging session. 
Hemostasis Phenotype n 
Number of 
Imaging Sessions 
Rate of 
Hemorrhage 
(mm
2
/min) 
Time to 
Hemostasis 
(min) 
1 Normal 
6 2 0.38 ± 0.31 24.55 ± 10.11 
2 Naïve Hemophilia A 
8 2 0.59 ± 0.41 > 30 
3 
Hemophilia A treated with FVIII to 
10% 
8 2 0.47 ± 0.32 25.26 ± 11.95 
4 
Hemophilia A expressing cFVIIa at 
1.3μg/ml 
4 2 0.56 ± 0.27 21.86 ± 8.72 
5 Naïve von Willebrand’s Disease 6 1 1.72 ± 0.43 23.98 ± 9.90 
6 
von Willebrand’s Disease treated 
with prophylactic VWF to 7% 
6 1 0.40 ± 0.34 23.21 ± 20.79 
 
Rate Significance 
   1 vs. 2 – p < 0.015 
   1 vs. 3 – p < 0.269 
   1 vs. 4 – p < 0.139 
   1 vs. 5 – p < 0.0000038 
   1 vs. 6 – p < 0.779 
 
 
TTH Significance 
   1 vs. 2 – p < 0.0015  
   1 vs. 3 – p < 0.804 
   1 vs. 4 – p < 0.792 
   1 vs. 5 – p < 0.741 
   1 vs. 6 – p < 0.735 
 
  
Rate of hemorrhage and time to hemostasis were also calculated for each dog 
using the sliding window method and time required to achieve zero or negative RH for at 
 46 
 
least 5 consecutive minutes, respectively. Significant differences in time to hemostasis 
were seen between normal dogs and dogs with naïve hemophilia A (p < 0.003). 
Treatment with infused FVIII to 10% and with gene therapy to express cFVIIa at 1.3 
µg/ml brought TTH to within normal limits (p < 0.986 and p < 0.718, respectively). 
Naïve VWD had significantly different RH than normal (p < 0.0063), which was 
corrected with prophylactic VWF administration (p < 0.242). Of note, the rate of 
hemorrhage in dogs expressing canine FVIIa was significantly different from normal (p < 
0.0003) even with corrected time to hemostasis measurements. These data are reported in 
Table 4.2.  
Table 4.2: Rate of hemorrhage and time to hemostasis measurements for each bleeding phenotype reported 
as mean ± standard deviation. Rate of hemorrhage was measured using a sliding window with a 10 minute 
kernel. Time to hemostasis was measured as the time at which RH became zero or negative. 
Hemostasis Phenotype n 
Number of 
Imaging Sessions 
Rate of 
Hemorrhage 
(mm
2
/min) 
Time to 
Hemostasis 
(min) 
1 Normal 
6 2 0.26 ± 0.23 21.92 ± 9.14 
2 Naïve Hemophilia A 
8 2 0.43 ± 0.33 > 30 
3 
Hemophilia A treated with FVIII to 
10% 
8 2 0.27 ± 0.21 21.69 ± 10.96 
4 
Hemophilia A expressing cFVIIa at 
1.3μg/ml 
4 2 0.51 ± 0.51 20.29 ± 10.40 
5 Naïve von Willebrand’s Disease 6 1 0.69 ± 0.17 21.5 ± 7.56 
6 
von Willebrand’s Disease treated with 
prophylactic VWF to 7% 
6 1 0.13 ± 0.03 26.6 ± 5.46 
 
Rate Significance 
   1 vs. 2 – p < 0.269 
   1 vs. 3 – p < 0.922 
   1 vs. 4 – p < 0.0003 
   1 vs. 5 – p < 0.0063 
   1 vs. 6 – p < 0.242 
 
 
TTH Significance 
   1 vs. 2 – p < 0.0030 
   1 vs. 3 – p < 0.985 
   1 vs. 4 – p < 0.718 
   1 vs. 5 – p < 0.874 
   1 vs. 6 – p < 0.359 
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4.2 Reproducibility of Time to Hemostasis and Rate of Hemorrhage 
Measurements 
 
4.2.1 Reproducibility after Multiple Imaging Sessions 
 
Reproducibility of TTH and RH measurements were assessed to determine the 
robustness of ARFI Monitored Hemostatic Challenge as an in vivo hemostatic assay. For 
reproducibility measures, normal, naïve hemophilia A, hemophilia A treated with infused 
FVIII to 10%, and hemophilia A expressing cFVIIa to 1.3 µg/ml dogs were imaged twice 
using identical protocols. Data were processed using both fixed ten minute windows for 
HR and time to 75% of maximum for TTH, which is designated as the Maximum 
Method, as well as calculating HR using a sliding window with a kernel of 10 minutes 
and TTH by determining the time at which HR becomes less than or equal to 0 mm
2
/min 
for at least 5 consecutive minutes, or the Rate Method. Statistical significance was 
determined using the two-sample t-test between imaging sessions of each phenotypic 
category for between-session reproducibility measures.  
After two imaging sessions the Rate Method appears to be highly reproducible 
while the Maximum Method was unable to measure statistically similar values for RH 
and TTH in select hemostatic phenotypes. These reproducibility results are reported in 
Figures 4.1 and 4.2, which provide graphical representation of the median and range of 
data collected for each group of dogs. The Maximum Method was not repeatable in 
normal and naïve hemophilia A dogs between imaging sessions, with significant 
differences found between measured RH from the two imaging sessions (p < 0.0142 and 
p < 0.0027). Additionally, the Maximum Method did not have reproducible TTH in 
normal dogs (p < 0.0027). The Rate Method was reproducible in all bleeding phenotypes. 
In both the Maximum and the Rate Methods expected differences between TTH in dogs 
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with naïve hemophilia and normal or treated dogs were maintained; this is consistent with 
results reported in Chapter 4.1. 
 
Figure 4.1: Reproducibility of Rate of Hemorrhage and Time to Hemostasis calculated using the 
Maximum Method. TTH was determined to be the time at which measured hemorrhagic area reaches 75% 
of the maximum measured area. TH was measured using discrete, non-overlapping 10 minute windows. 
Boxplot showing the median (red line), 25
th
 and 75
th
 percentiles (blue box), and range (dashed lines) of data 
for all hemostatic phenotypes. Exp. 1 and Exp. 2 correspond to imaging sessions 1 and 2, respectively. N is 
the total number of dogs in each imaging session. 
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Figure 4.2: Reproducibility of Rate of Hemorrhage and Time to Hemostasis calculated using the Rate 
Method. TTH was determined to be the time at which measured rate of hemostasis reaches or dips below 0 
mm
2
/min. TH was measured using a sliding 10 minute window. Boxplot showing the median (red line), 
25
th
 and 75
th
 percentiles (blue box), and range (dashed lines) of data for all hemostatic phenotypes. Exp. 1 
and Exp. 2 correspond to imaging sessions 1 and 2, respectively. N is the total number of dogs in each 
imaging session. 
Reproducibility measurements using ARFI monitored hemostatic challenge were 
directly compared to hemostatic measures found using primary saline bleeding time 
(1°SBT), primary cuticle bleeding time (1°CBT), and secondary cuticle bleeding time 
 50 
 
(2°CBT). 1°SBT is completed by immersing the tip of the ear in 37°C 0.9% saline for 2 
minutes. The tip is then cut with a scalpel blade over ~0.5 cm, and then resubmerged in 
the saline. Bleeding is observed and the time to cessation of bleeding is noted. Normal 
hemostasis is defined as cessation of bleeding in less than 5 minutes, and abnormal is 
defined as greater than 15 minutes. 1°CBT and 2°CBT follow a similar protocol using the 
paw to monitor bleeding. A guillotine-style nail clipper is used to create a primary cut in 
the nail located at the quick. The bleeding nail is submersed in warm saline, as in saline 
bleeding time protocol, and the time to cessation of bleeding for a full minute is recorded 
as the primary bleeding time. The secondary bleeding time is measured by reinjuring the 
nail using the guillotine-style nail clippers two hours after the first injury, monitoring the 
bleeding in warm saline, and recording the time that bleeding ceases for a full minute 
[34].   
Table 4.3 illustrates the lack of reproducibility in this large animal model 
hemostatic assay. Primary and secondary bleeding measurements were reproducible in 
normal dogs, with 6 of 6 exhibiting cessation of bleeding in less than five minutes on two 
separate occasions. However, naïve hemophilia A showed a secondary cuticle bleeding 
time of greater than 15 minutes, as expected, in only 4 of the 8 dogs. This was repeatable 
in 1 of these 4. Six of 8 naïve hemophilia A dogs had unclear endpoints, in which 
bleeding began anew after appearing to cease during the observation period. Treatment 
with FVIII did not bring hemophilic dogs within the normal range, with one dog 
exhibiting cessation of bleeding greater than 15 minutes. Only one dog showed normal 
bleeding cessation after infusion with FVIII; however it was a repeatable measurement 
 51 
 
for this dog. The Von Willebrand’s Disease population had no dogs within normal 
bleeding cessation, and 3 of 6 dogs stopped bleeding in greater than 15 minutes.  
Table 4.3: Reproducibility of primary and secondary cuticle and saline bleeding measures in 6 normal, 8 
naïve hemophilia A, 8 hemophilia A with infused FVIII, and 6 naïve VWD dogs. Bleeding disorders are 
expected to have secondary measurements of greater than 15 minutes, which should be reproducible 
particularly in naïve Hemophilia A. Normal dogs are expected to have primary measurements of less than 5 
minutes. Unclear endpoints occurred when bleeding slows drastically, and then suddenly increases during 
the observation period. 
 
< 5 minutes on 
primary 
measurement 
> 15 minutes 
on secondary 
measurement 
Reproducible 
Excessive 
Bleeding 
Unclear 
Endpoints 
Normal  
(n = 6) 
6/6 -- 6/6 -- -- 
Naïve Hemo A 
(n = 6) 
-- 4/8 1/4 6/8 6/8 
Hemo A + 
FVIII 
(n = 8) 
1/8 1/8 1/1 -- -- 
VWD 
(n = 6) 
-- 3/6 -- -- -- 
 
4.2.2 Within Dog Reproducibility 
 
Within dog reproducibility was assessed to determine if, for each dog imaged 
twice, TTH values and RH values from imaging session 1 were reproducible in imaging 
session 2. Normal TTH was defined as time to hemostasis of less than 30 minutes. TTH 
greater than 30 minutes has been shown via ARFI Monitored Hemostasis to be typical of 
hemostatic disorders, and is particularly evident in naïve Hemophilia A. Similarly, ARFI 
derived RH have shown that hemostatically normal dogs typically have RH far less than 
1 mm
2/min while dogs with von Willebrand’s Disease have RH greater than 1 mm2/min.  
 The Maximum Method for measurement of TTH and RH yielded inconclusive 
within-dog reproducibility results, shown in Table 4.4. Only half of the normal dogs had 
reproducible TTH measurements. TTH measured for naïve hemophilia A dogs was 
consistently greater than 30 minutes after both imaging sessions. Treatment with infused 
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FVIII in these dogs brought three of eight dogs within normal range, all of whom 
reproducibly had TTH measurements under 30 minutes. Gene therapy to express cFVIIa 
appeared to be a more successful treatment, with four of four dogs having TTH within 
normal limits, and three of those four exhibiting reproducible results after the second 
imaging session. Almost all of the dogs, regardless of hemostatic phenotype, were within 
normal limits for RH. These RH values appear highly reproducible after the second 
imaging session.  
Table 4.4: Reproducibility of TTH and RH calculated using the Maximum Method in 6 normal, 8 naïve 
hemophilia A, 8 hemophilia A with infused FVIII, and 4 naïve hemophilia A expressing cFVIIa. Normal 
dogs are expected to have TTH measurements of less than 30 minutes and RH of less than 1 mm
2
/min, 
which should be reproducible after the second imaging event. 
Maximum 
Method 
TTH < 30 
minutes  
Reproducible 
RH  < 1 
mm
2
/min 
Reproducible 
Normal  
(n = 6) 
6/6 3/6 5/6 5/5 
Naïve Hemo 
A 
(n = 8) 
0/8 8/8 7/8 7/7 
Hemo A + 
FVIII 
(n = 8) 
3/8 3/3 7/8 7/7 
Hemo A 
exp. cFVIIa 
(n = 4) 
4/4 3/4 3/4 3/3 
 
The Rate Method for calculating TTH and RH demonstrated greater 
reproducibility between groups than the Maximum Method; this trend appears to 
continue in within-dog reproducibility measurements as well.  Five of six normal dogs 
had TTH less than 30 minutes, with reproducible TTH measurements in 4 of those 5 
dogs. Naïve Hemophilia A has identical within-dog reproducibility as with the Maximum 
Method, however treatment with FVIII and gene therapy to express cFVIIa appear to 
have more robust results when calculating RH and TTH with the Rate Method. After 
infusion with FVIII, 6 of 8 naïve hemophilia A dogs were brought within normal limits, 
and all six of these measurements were reproducible. Similarly, all four dogs that 
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underwent gene therapy had TTH less than 30 minutes. Unfortunately, only two of these 
four were reproducible after the second imaging session. Rate of hemorrhage 
measurements were highly reproducible in all hemostatic phenotypes included herein.  
 
Table 4.5: Reproducibility of TTH and RH calculated using the Rate Method in 6 normal, 8 naïve 
hemophilia A, 8 hemophilia A with infused FVIII, and 4 naïve hemophilia A expressing cFVIIa. Normal 
dogs are expected to have TTH measurements of less than 30 minutes and RH of less than 1 mm
2
/min, 
which should be reproducible after the second imaging event. 
Rate 
Method 
TTH < 30 
minutes 
Reproducible 
RH < 1 
mm
2
/min 
Reproducible 
Normal  
(n = 6) 
5/6 4/5 6/6 6/6 
Naïve Hemo 
A 
(n = 8) 
0/8 8/8 7/8 6/7 
Hemo A + 
FVIII 
(n = 8) 
6/8 6/6 8/8 8/8 
Hemo A 
exp. cFVIIa 
(n = 4) 
4/4 2/4 1/4 1/1 
 
 
Regardless of the method used to calculate time to hemostasis and rate of 
hemorrhage, ARFI Monitored Hemostatic Challenge appears to be highly reproducible. 
Primary and secondary cuticle and saline bleeding times are unable to compete in terms 
of reproducibility. Additionally, ARFI Monitored Hemostatic Challenge is more reliably 
able to determine hemostatic disorders than cuticle and saline bleeding times; no dogs 
with naïve hemophilia A were considered normal using both the Maximum Method and 
the Rate Method, whereas only half the dogs with naïve hemophilia A were considered 
abnormal when using cuticle and saline bleeding times.  
 54 
 
4.3 Gene Therapy in Dogs 
 
ARFI Monitored Hemostatic Challenge has demonstrated the efficacy of FVIII 
infusion in hemophilic dogs, as well as gene therapy for expression of cFVIIa in a small 
number of hemophilic dogs. Gene therapy is a promising therapeutic for clinical 
applications in individuals with inherited bleeding disorders. Expression of canine FVIIa 
is shown to reduce a dog’s reliance on on-demand therapeutic agents after injury. Figure 
4.6 illustrates the effects of gene therapy to express FVIIa on a single FVIII deficient 
dog. Infused FVIII was administered after 30 minutes to combat excessive bleeding prior 
to gene therapy, shown in the top row of Figure 4.3. Prior to gene therapy, this dog 
exhibits a typical hemophilic bleeding profile in which a true measurement of hemostasis 
is not achieved due to safety constraints. After injury the dog continues bleeding slowly 
without cessation until on-demand therapies are administered. The plot of RH vs. time 
indicates multiple small instances of transient hemostasis when the rate is equal to or less 
than 0 mm
2
/min.  
After expression of cFVIIa this dog was capable of sustained clotting almost 
immediately after injury. There is a slight lag time between the time of injury and the 
beginning of data acquisition, in this case about 20 seconds of lag, resulting in an initial 
accumulation of extravasated blood that immediately begins decreasing in area, as seen in 
the plot of measured hemorrhagic area vs. time on the bottom row of Figure 4.3. This 
FVIII deficient dog is capable of achieving and maintaining hemostasis without the aid of 
infused FVIII after gene therapy. It appears that prophylactic gene therapy has reduced 
the need for on-demand clotting agents after injury. TTH and RH were calculated using 
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the Rate Method, in which initial TTH is denoted as the first zero crossing of RH 
followed by 5 consecutive minutes of negative or zero RH values. 
Prior to therapy for this individual dog, it does not appear that continued 
hemostasis is achieved; there are many periods of transient hemostasis without extended 
cessation of bleeding. After gene therapy it appears that this particular dog had excessive 
bleeding between vessel injury and the beginning of ARFI acquisition, at which point the 
dog developed a long-lasting clot at the site of injury. However, immediate hemostasis 
after injury seems unlikely and more examples are needed to validate this result. 
Additionally, fluctuations in RH after gene therapy appear periodic in nature, which may 
suggest that transient instances of hemostasis may be the result of normal fluctuations in 
cardiac pressure. 
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Figure 4.3: Area of hemorrhage and rate of hemorrhage vs. time plots for a single FVIII deficient dog 
before (top) and after (bottom) gene therapy to express canine FVIIa. The Rate Method was used for data 
analysis. 0 mm
2
/min is denoted on RH plots by a dashed black line. Prior to gene therapy this dog was 
given infused FVIII at 30 minutes to combat excessive bleeding. 
 
Initial results are reported below for a FVII deficient dog scheduled for gene 
therapy to express zymogen FVII. The zymogen is inactivated FVII. This particular dog 
exhibited the inability to form a lasting clot, evidenced by the continued fluctuations in 
measured hemorrhagic area over time in Figure 4.4. Additionally, the rate of hemorrhage 
over time was slightly elevated during periods of bleeding. Short periods of transient 
hemostasis were observed without significant cessation of bleeding (Figure 4.5).  
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Figure 4.4: Measured hemorrhagic area vs. time in a FVII deficient dog. The data was fit using the Rate 
Method. Raw data measurements are indicated by red circles. 
 
Figure 4.5: Rate of hemorrhage calculated from the data presented in Figure 4.4. Note the multiple 
instances of transient hemostasis after the initial injury. 
Chapter 5  
 
Validation of ARFI Monitored Hemostatic Challenge Derived Metrics 
 
5.1 Autologous Infusion Protocol for Validation Studies 
 
Validation studies were performed to determine whether ARFI calculated rate of 
hemorrhage and measured time to hemostasis are physiologically relevant. Dogs with 
normal bleeding phenotypes were supplied by the Francis Owen Blood Research 
Laboratory and placed under general anesthesia, as described in Chapter 3. The dogs 
were placed in a prone position, and the ultrasonic transducer was located above a 
peripheral vessel in the hind limb. Vessels of interest were located 25-30 mm deep in the 
muscle tissue. Any vasculature outside of this range was not considered due to 
restrictions in the depth of field of ARFI displacement measurements.  
The validation studies differ from the ARFI-monitored hemostatic challenge in 
that injury is not introduced into the vessel. Rather, citrated whole blood was injected into 
the hind limb via a syringe pump at a known rate for a specified time. The injected blood 
was meant to mimic natural bleeding after injury to the vessel. Since the injected time 
and rate are predetermined and the injected volume is theoretically known, ARFI 
measurements of TTH and RH should reflect these values. 
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Several iterations were tested to determine an ideal validation protocol. Initially, 
proof-of-concept experiments were completed in a tissue mimicking phantom to 
determine the feasibility of utilizing the syringe pump while executing ARFI imaging. 
Pork sirloin roast and evaporated milk were acquired from a local grocery store to be 
used as tissue and blood mimics, respectively. The pork was placed in a water bath and 
secured using clamps. Ten ml of evaporated milk was loaded into a 10 ml plastic syringe 
connected to a 24 gauge needle with a 7” MicroCLAVE Smallbore T-Connector (Abbott 
Laboratories, North Chicago, IL USA).  The syringe was placed into a Standard PHD 
ULTRA™ CP Syringe Pump (Harvard Apparatus, Holliston, MA USA). The needle was 
inserted into the pork elevationally with respect to the transducer and positioned using 
ultrasound guidance so that the needle tip was slightly visible at approximately 16 mm in 
depth. An initial ARFI acquisition was taken as a baseline measurement before any 
evaporated milk was introduced into the pork. The syringe pump was then turned on at a 
rate of 0.5 ml/min with serial ARFI acquisitions occurring every minute thereafter for 20 
minutes.  
Problems encountered during this experiment resulted from the properties of 
imaging in dead tissue, such as pork roast, versus imaging in healthy tissue. Although 
pork is a suitable tissue mimic acoustically, it does not behave as healthy muscle does 
when fluid is introduced into the interior of the tissue sample. The evaporated milk was 
able to quickly leak out of the pork through regions where the muscle had been broken 
down, and it was deemed impossible to create a hematoma-like region in the pork. It was 
determined that transition into healthy muscle tissue was necessary to facilitate validation 
measurements.  
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In each experiment, citrated blood was transferred to a sterile 10 ml plastic 
syringe with a Luer-Lok tip (Becton, Dickinson and Co., Franklin Lakes, NJ USA), and 
attached to a large gauge needle using a 7” MicroCLAVE Smallbore T-Connector 
(Abbott Laboratories, North Chicago, IL USA). The syringe was fixed into Standard 
PHD ULTRA™ CP Syringe Pump (Harvard Apparatus, Holliston, MA USA), and the 
pump was programmed to inject the full 10 ml of citrated blood into the hind limb. The 
injection needle was placed using ultrasound guidance so that the tip was localized above 
the vessel wall without actually puncturing the vessel. Placement was then adjusted so 
that shadowing resulting from the needle in the field of view was minimized.  
To validate ARFI measurements of hemostasis multiple infusion times and rates 
of infusion were used. Table 5.1 illustrates various changes implemented over the course 
of protocol development.  Each iteration was repeated at least twice to determine 
reproducibility of results. The first two experiments utilized a 12 gauge needle at the 
injection site with 0.5 ml/min infusion rate lasting approximately 20 minutes, for a total 
of 10 ml infused blood. ARFI acquisition was focused at approximately 20 mm in depth. 
Needle placement for this protocol was located lateral to the transducer, with the needle 
pulled slightly out of the field of view as seen in Figure 5.1. 
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Figure 5.1: Lateral placement of needle in initial validation studies. 
 
Figure 5.2: Elevational placement of needle in initial validation studies 
 
 
This lateral placement was found to cause excessive shadowing beneath the 
needle due to the constant presence of the needle in the edge of the imaging plane. 
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Additionally, concerns were raised that this placement was not introducing blood into the 
field of view, as ARFI visualization required that the blood flow in a single direction 
toward the center of the transducer. To combat this issue, subsequent experiments placed 
the needle in the center of the transducer laterally, with the needle tip entering the 
imaging plane elevationally as seen in Figure 5.2.  
Initial experiments also demonstrated the need to determine where the blood was 
accumulating in the muscle tissue prior to data acquisition. The needle tip in the first two 
experiments was localized around 20 mm in depth, therefore 20 mm was chosen as the 
focal depth. However, it was observed that blood did not necessarily accumulate 
proximal to the needle. It could travel up the needle track in the tissue, pooling closer to 
the surface of the skin; it could also pool deeper in the tissue where facial layers met. A 
scouting infusion was used in subsequent experiments due to the uncertainty of where the 
infused blood localized. The scouting infusion consisted of 0.25 – 0.5 ml of blood infused 
at a single rate after needle placement. As the blood entered the tissue, sparkling could be 
observed in the B-mode image on the ultrasound scanner. The sparkling behavior in B-
mode was indicative of fluid flowing in the muscle. This indicated where the blood was 
pooling, and allowed for more accurate focal depth selection during ARFI acquisitions. It 
was later determined that multiple focal depths would more accurately capture any 
regions of pooling blood by expanding the depth of field in ARFI experiments. Five mm 
above the focal depth is the ideal range for data acquisition for this application, as a 
maximum amount of applied force provides more accurate blood pixel separation. The 
utilization of two focal depths expanded this range to approximately 10 mm, giving a 
more thorough image of where blood pooled.  
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The appropriate needle size was determined for validation applications. In the 
standard ARFI hemostatic challenge a 12 gauge needle was used to cause injury to the 
vessel. The same 12 gauge needle was therefore first used to introduce infused blood into 
the muscle. It was found that the shadowing caused by this sized needle was enough to 
distort any reliable measurements obtained from ARFI data due to the needle remaining 
in the tissue during serial ARFI acquisitions. Additionally, the large needle caused 
unknown amounts of bleeding from tissue damage, which was not accounted for in pre-
determined rates and volumes of infusion. A smaller 22 gauge needle was then utilized. 
The 22 gauge needle successfully minimized shadowing in the image, with only a small 
region below the needle containing noise, while simultaneously minimizing bleeding 
from tissue damage. An 18 gauge needle was also utilized for two experiments; however 
it did not seem to successfully introduce more blood to a region with less shadowing 
therefore the protocol returned to the 22 gauge needle.  
Infusion rates used varied between 0.25 ml/min and 1 ml/min for volumes ranging 
from 2 ml to 10 ml, as shown in Table 5.1. These rates and volumes were selected to 
verify that ARFI is able to measure relativistic differences in bleeding rate proportional to 
the true differences in infusion rates. Current implementation of ARFI Monitored 
Hemostatic Challenge uses a linear ultrasonic probe, resulting in 2D cross sections of 
hemorrhage. Absolute bleeding rates cannot be measured, even with known infusion 
rates, due to the behavior of blood inside soft tissue. It is expected that once introduced 
into the muscle, citrated blood will flow away from the site of introduction in multiple 
directions.  
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Since current ARFI methods can only capture one dimension of this motion, 
relativistic measurements of rate must be used to validate ARFI measurements. If citrated 
blood is introduced into the muscle tissue at multiple rates over the course of a single 
experiment and ARFI is able to determine the ratio of these introduced rates (i.e. citrated 
blood is infused two-times slower in the first ten minutes than in the last ten minutes), 
then ARFI measurements of HR can be validated using this protocol. Additionally, 
known infusion times were utilized to determine if ARFI techniques could reliably 
measure the time at which bleeding ceased (directly related to the time at which the 
infusion pump was stopped).  
Figure 5.3 shows results from a single validation study in which expected TTH 
were measured at 128% and 133%, respectively, of the actual cessation of the infusion. 
Waiting times after the completion of each infusion were used to provide adequate time 
for the infused blood to settle. Infusion rates were not accurately measured, as the 
maximum rate measured for the fast rate (left hand plots in Figure 5.3) should be 
approximately twice that measured for the slow rate (right hand plots in Figure 5.3). This 
data was measured using a 22 gauge needle to inject citrated blood at a rate of 0.25 
ml/min and 0.5 ml/min for a volume of 4.5 ml at each rate. Two focal depths were used 
to expand relevant ARFI measurements, and 20 minutes of waiting followed each 
infusion time to allow the citrated blood to diffuse away from the ARFI field of view. 
Elevated measured TTH compared to actual TTH may have been caused by 
continued flow of citrated blood into the field of view after the pump was turned off. 
Citrated blood does not coagulate like untreated blood, therefore continued ARFI 
excitations may have resulted in continuous streaming of citrated blood during data 
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acquisition. However, the general profiles of measured hemorrhagic area vs. time 
followed an expected shape, in which the measured area increased until an approximate 
cessation of pumping, after which point the measured area plateaued and began to 
decrease. 
Table 5.1: Parameters for each iteration of the validation protocol – Needle size (gauge), needle 
position (lateral or elevational to transducer), focal depth (mm), if a scouting infusion was used, 
whether multiple sequences (single push, no push, and double push) were used, infusion rates and 
the order they were utilized (ml/min), the total infused volume for each rate (ml), the total 
infusion time for each rate (min), and the waiting time before or after each infusion. 
 Exp 1 
Exp  
2 
Exp  
3 
Exp  
4 
Exp  
5 
Exp 
6 
Exp 
7 
Exp  
8 
Exp  
9 
Exp  
10 
Needle 
Size 
(gauge) 
12 12 22 22 22 18 18 22 22 22 
Needle 
Pos. 
Lat Lat Ele Ele Ele Ele Ele Ele Ele Ele 
Focal 
Depth 
(mm) 
20 20 23 23 
20 
25 
20 
25 
20 
25 
18 
23 
18 
23 
23 
28 
Scouting 
Infusion 
-- -- Yes Yes Yes Yes Yes Yes Yes Yes 
Multiple 
Seq 
Single Single Single 
Single  
No Push 
Double  
Single  
No Push 
Double 
Single  
No Push 
Double 
Single  
No Push 
Double 
Single  
No Push 
Double 
Single  
No Push 
Double 
Single  
No Push 
Double 
Infusion 
Rate(s) 
and 
Order 
(ml/min) 
0.5 0.5 
0.25 
0.5 
0.5 
0.25 
0.25 
0.5 
0.5 
0.25 
0.25 
0.5 
0.25 
0.5 
0.25 
0.5 
1 
0.25  
0.5 
1 
Infusion 
Volume 
(ml) 
10 10 
4.5 
4.5 
4.5 
4.5 
4.5 
4.5 
4.5 
4.5 
4.5 
4.5 
2 
2 
2 
3 
4 
2 
3 
4 
Infusion 
Time 
(min)  
20 20 
18 
9 
9 
18 
18 
9 
9 
18 
18 
9 
8 
4 
8 
6 
4 
8 
6 
4 
Waiting 
Time 
10 
min 
after  
10 
min 
after 
20 min 
after 
each 
infusion 
20 min 
after 
each 
infusion 
20 min 
after 
each 
infusion 
20 min 
before, 
20 
minutes 
after each 
infusion 
20 min 
before, 
20 
minutes 
after each 
infusion 
5 min 
after 
final 
infusion 
20 min 
after 
final 
infusion 
30 min 
after 
final 
infusion 
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Figure 5.3: Measured blood area vs. time and associated rate measurements calculated using the Rate 
Method for validation of ARFI Hemostatic Challenge. Two rates, 0.5 ml/min (left and plots) and 0.25 
ml/min (right hand plots) were used to introduce citrated blood to the hind limb of a phenotypically healthy 
dog. The TTH measured for the fast rate was 12 minutes, and for the slow rate was 23 minutes. Expected 
TTH values are 9 and 18 minutes, respectively. 
5.2 Future Modifications to Validation Methods 
 
Major disadvantages in the design of this protocol were encountered due to the 
use of a 2D ultrasound probe. Since the behavior of introduced blood in muscle tissue is 
not known prior to the experiment, the placement of the transducer and selection of the 
focal depth are based on what little a priori knowledge is available from the scouting 
infusion and knowledge of the needle location. Since boundaries between muscles, 
pockets in the muscle tissue, fat, and other soft tissues are located slightly differently in 
each dog, it is impossible to know the exact location of where the majority of introduced 
blood will pool or the geometry of the pool that develops. The placement of the 
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ultrasound transducer is chosen to ideally intersect the largest region of pooled blood in 
the axial and lateral directions.  
The use of a 3D imaging transducer in future studies will facilitate accurate 
measurement and visualization of pooled blood in muscle tissue. Since 3D ultrasound 
probes are able to visualize the elevational dimension in tissue, they should be able to 
render detailed information about the behavior of extravasated or introduced blood. The 
rate of bleeding measured with 3D probes will be directly relatable to infusion rates in 
validation studies with volumetric analysis, compared to the cross sectional analysis 
presented in Chapter 5.1. Additionally, information about the size, shape, and behavior of 
the clot may be determined from 3D ultrasonic imaging. If a thrombus appears stable in a 
given cross-sectional slice, such as when hemostasis appears to have been reached using 
ARFI Monitored Hemostatic Challenge, current 2D methods cannot determine if 
bleeding has indeed ceased or if it is continuing outside the current field of view.  
Volumetric imaging may provide valuable information about the location of thrombi with 
respect to the source of hemorrhage that 2D methods are inadequately suited for. 
Initial 3D studies with blood mimicking materials in phantoms have demonstrated 
that volumetric ARFI is able to distinguish extravasated blood pixels using the same 
methodology presented in Chapter 2.3.1. Figures 5.4 and 5.5 show 3D data obtained by 
translating an imaging probe in steps of 0.5 mm elevationally over a 1.25 cm distance 
using a motorized digital translation stage. A fluid bolus was made by securing whole 
milk in a latex casing, then embedding this into a gelatin tissue mimicking phantom. The 
volume of the milk bolus was approximately 1.02 cc. An estimated volume contained 
within the blood mimic was calculated as 0.843 cc; the estimated measurement was 
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slightly smaller than the actual volume due to the positioning of the image acquisition 
plane – a small portion of the blood mimic was cut off in the imaging process. As a proof 
of concept, this particular 3D data set shows that ARFI is able to distinguish blood mimic 
from the soft tissue mimic surrounding it, and that accurate volumetric measurements are 
possible. 3D application of ARFI discrimination of hemostatic measurements will allow 
for further validation studies to accurately measure time to hemostasis and bleeding rate 
in vivo.  
 
Figure 5.4: Hybrid B-mode/ARFI images showing a volume of blood mimic enclosed inside of a tissue 
phantom. Each slice shows a cross section of the volume in Figure 6.2. Blood mimic has been identified as 
colored pixels. 
 
Figure 5.5: Hybrid B-mode/ARFI volumetric image of blood mimic enclosed inside of a tissue phantom. 
Blood mimic has been identified as colored pixels 
Chapter 6  
Conclusions and Future Directions   d 
6.1 New Technology for ARFI Monitored Hemostatic Challenge 
 
The results presented in this thesis demonstrate that ARFI is capable of 
reproducibly measuring time to hemostasis and rate of hemorrhage. The results of 
Chapter 3 show that between imaging sessions and within dog measurements are highly 
reproducible when calculating the RH and TTH using the Rate Method. Calculation of 
rate of hemorrhage using an overlapping, sliding window with a kernel length of 10 
minutes also renders reproducible results within-dog, as shown in Chapter 4.2.2, as does 
the measurement of time to hemostasis as the time at which rate becomes equal to or less 
than 0 mm
2
/min for at least 5 consecutive minutes.  
Validation techniques presented in Chapter 5 indicate that further work is 
necessary to determine the accuracy of TTH and RH measurements. Current 2D ARFI 
imaging is unable to accurately measure relativistic changes in the rate of infused, 
citrated blood. Resulting time to hemostasis measurements are also slightly skewed using 
this validation protocol. The largest source of error arises from conventional ARFI 
imaging, which is only capable of providing cross-sectional information about the 
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subcutaneous behavior of endogenous or infused blood. The introduction of 3D ARFI 
imaging will aid in validating these studies using volumetric imaging.  
Future work for technology development in this study will include volumetric 
imaging, development of algorithms to expand the field of view in ARFI imaging, and 
automation of data processing.  As proposed in Chapter 5.2, future work in volumetric 
imaging will provide a higher level of clinically relevant detail in hemostatic 
measurements. Changes in hemorrhagic volume will more accurately indicate HR and the 
onset of hemostasis than results obtained with 2D imaging.  
Expanded field of view during ARFI acquisitions will also provide more data for 
accurate hemostatic assessment. Current protocols are limited to a 5 mm axial field over 
which ARFI displacements are reliably measured. Expansion of this field to 10 mm was 
achieved by imaging at two focal depths in validation studies; however the 
implementation of multiple sequences at multiple focal depths takes away from the 
potential for real time imaging by reducing the frame rate.  
Current data processing techniques presented in the Maximum and Rate Methods 
require extended periods of time for successful processing of data acquired from 
individual dogs. Automation of this technique would increase the efficiency of ARFI 
monitored hemostatic challenge for implementation in real time or online processing. 
Transition of data to an offline computational center, then requiring operator input during 
the data processing protocol is a major disadvantage that requires automation before this 
research can be successfully translated into the clinic.  
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6.2 Clinical and Pre-Clinical Applications 
 
Future work on clinical and pre-clinical implementation provides multiple 
applications for this technique. This thesis focused on applications of ARFI 
measurements in dog models of inherited bleeding disorders. However, measurements of 
time to hemostasis and bleeding rate are also applicable to acquired bleeding disorders. 
Acquired disorders can be induced via medication, such as in patients on high doses of 
antithrombotics. Dose response metrics to antithrombotic medications would be relevant 
for the treatment of individuals on such medications. Acquired disorders can be induced 
in a normal dog population, and dose response curves can be determined using ARFI 
derived TTH and RH metrics.  
Another application of ARFI monitored hemostasis in the clinic is to determine 
the mechanical properties of hemorrhage. Data already acquired from the dogs imaged 
and presented in this thesis contains information about the recovery profiles of soft tissue, 
luminal blood, and extravasated blood. Further investigation into the mechanical 
properties of extravasated blood contained within soft tissue may provide information 
about the strength of clots that form during imaging, which could be used as a third 
hemostatic metric when assessing hemostasis in vivo.  
Extensive research is required before ARFI hemostatic measurements can be 
translated into routine clinical use; however this thesis suggests that, even with the 
limitations caused by imaging in two dimensions, ARFI characterization of hemostasis is 
highly reproducible and highly adaptable based on specific data processing and noise 
reduction algorithms utilized. ARFI-Monitored Hemostasis is able to distinguish between 
different hemostatic phenotypes and the effects of treatments ranging from infused FVIII 
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to gene therapies. ARFI-Monitored Hemostatic Challenge is capable of advancing 
research protocols for the development of future therapeutics for hemostatic disorders 
while providing a safe, in vivo assay for translation into the clinic. Future work will serve 
to further prove the robustness of this technique. 
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